Boscari, Federico
Ferretto, Sara
Cavallin, Francesco
Fadini, Gian Paolo
Avogaro, Angelo
Bruttomesso, Daniela http://orcid.org/0000-0002-2426-8955
Article History
Received: 27 January 2022
Accepted: 17 March 2022
First Online: 13 April 2022
Change Date: 5 August 2022
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note.
Declarations
:
: FB has received lecture fees from Abbott, Roche, Eli Lilly, Novo-Nordisk and Sanofi Aventis. DB has received lecture fees from Abbott, Astra Zeneca, Eli Lilly, Sanofi Aventis, Roche Diagnostics. GPF received grants or consultancy or lecture fees from Abbott, AstraZeneca, Boehringer, Lilly, MSD, Novartis, Novo Nordisk, Mundipharma, Servier, Sanofi, Takeda. AA received research grants, lecture or advisory board fees from Merck Sharp & Dome, AstraZeneca, Novartis, Boeringher-Ingelheim, Sanofi, Mediolanum, Novo Nordisk, Lilly, Servier, and Takeda. Other authors declare no conflict of interest in connection with submitted material.
: The study was performed at the Division of Metabolic Diseases of the University Hospital of Padova (Padua, Italy) following the Helsinki Declaration of 1964 and its later amendments and in agreement with national regulations. The study was conceived as a retrospective data collection and cleared by the local Ethical Committee (protocol number 151n/AO/21).
: All subjects provided written informed consent to use clinical data for research purposes.